Description: Aldeyra Therapeutics, Inc. (Aldeyra) is a biotechnology company. The Company is focused primarily on the development of products to treat immune-mediated, inflammatory, orphan, and other diseases that are thought to be related to a naturally occurring toxic chemical species known as free aldehydes. The Company is developing NS2. NS2 is a product candidate that is designed to trap and allow for disposal of free aldehydes, for the treatment of diseases, which include Sjogren-Larsson Syndrome (SLS), discoid lupus, acute anterior uveitis and ocular rosacea with meibomian gland dysfunction. Aldeyra is also developing aldehyde traps distinct from NS2. As of April 7, 2014, it had evaluated NS2 in a Phase I clinical trial in 48 volunteers.
Home Page: www.aldeyra.com
ALDX Technical Analysis
131 Hartwell Avenue
Lexington,
MA
02421
United States
Phone:
781 761 4904
Officers
| Name | Title |
|---|---|
| Dr. Todd C. Brady M.D., Ph.D. | CEO, Pres & Director |
| Dr. Stephen G. Machatha Ph.D. | Chief Devel. Officer |
| Mr. Bruce Greenberg CPA, M.B.A. | VP of Fin., Interim CFO & Treasurer |
| Mr. Kelly Mizer | VP of Commercial Strategy & Operations |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.2385 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2014-05-02 |
| Fiscal Year End: | December |
| Full Time Employees: | 15 |